14 news items
NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
NKGN
12 Jun 24
natural killer ("NK") cell therapeutics, today presented details on its novel allogeneic blood-derived NK cell therapy ("SNK02") commercial
NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
NKGN
3 Jun 24
natural killer ("NK") cell therapeutics, today announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen Biotech, will present
Spotlighting Unexplored Stocks in Focus: NKGN, INBS, BTBT, PRSO, MGOL
BTBT
INBS
MGOL
24 May 24
biotech firm, NKGen Biotech is focused on developing and commercializing allogeneic, autologous, and CAR-NK natural killer cell therapies. On May 20
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
NKGN
23 May 24
on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced
Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session
AKAN
AKTS
BCAN
20 May 24
. Shineco recently announced that its subsidiaries Fuzhou Medashan Biotechnology and Kaifeng Yixi Biotechnology invented a new natural active water-soluble
exo6ftcb7jb0pnnthv6k6sw90kp0xg07gp75ec48w9lt6l4ei5xsjkld6td
NKGN
20 May 24
, autologous enhanced natural killer cell therapy, delivered in highest dose to date, demonstrates preliminary clinical benefit without any drug
o68iqef71axw7p839xt1abu1z9mcn07 nuw06dc0q2ib4aij2m3
NKGN
16 May 24
natural killer ("NK") cell therapeutics, today announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen, will present highlights
stwy9q0n3juzypit7iavrvqvmquw4yu7j609y0c7omzvpbfursqqw2mwrv
NKGN
29 Apr 24
natural killer ("NK") cell therapeutics, today announced that the U.S. Food and Drug Administration ("FDA") has cleared the Company's Investigational New
hcjo9 zhi2
NKGN
25 Apr 24
on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced
s1ivoc9ylgqx713crqru
NKGN
24 Apr 24
natural killer ("NK") cell therapeutics, today announced an online publication at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual
pvhl8rn9nx10t6v3hpl6ywmjz4ub2zo70t0e2d2xpwi6hp8ynjhc6ikxg
NKGN
18 Apr 24
-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell
mlizbbdh h3
NKGN
11 Apr 24
natural killer cell therapeutics, today announced that it has closed $5 million in second lien convertible loan funding with a term of 30 months
7b0ok7ihnsgtw66tiakqbp5e6i37waw6t5
NKGN
25 Mar 24
, and CAR-NK Natural Killer ("NK") cell therapeutics, today presented additional Phase 1 clinical trial data on the use of its investigational
35momgtw4g4dnccj4nh8ve1vpmwxsrbh71il7ft4rgivrjct
NKGN
25 Mar 24
-NK Natural Killer ("NK") cell therapeutics, today presented additional Phase 1 clinical trial data on the use of its investigational autologous NK
- Prev
- 1
- Next